Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (vol 15, pg 613, 2020)
Open Access
- 1 December 2020
- journal article
- correction
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 34 (6), 889
- https://doi.org/10.1007/s10557-020-07023-8
Abstract
The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘intravThis publication has 1 reference indexed in Scilit:
- Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Cardiovascular Drugs and Therapy, 2020